QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)

Medtronic: oversold, overextended high yield reversal in play

medtronic logo on sign outside corporate headquarters

Key Points

  • Medtronic shares are up following the Q2 release, indicating a reversal is in play. 
  • The company showed strength on the top and bottom lines and improved guidance for the year. 
  • The dividend and share repurchase outlook are substantial and getting healthier by the quarter. 
  • 5 stocks we like better than Medtronic

After two years of correction and downtrend, providing ample incentive to buyers all along the way, medical device maker Medtronic NYSE: MDT has finally reached its bottom, and the reversal is on. The Q2 results confirm normalization in the wake of the COVID bubble and a solid trajectory for growth that is nearly irresistible for value-minded income investors.

Growth isn't expected to be robust for this medtech stock but to continue at a pace sufficient to sustain share price value, the dividend, and distribution growth outlook, which is substantial. The question is whether this reversal will complete and turn into a rally or the market will become range-bound at its current levels.

Medtronic had a steady quarter, margin impressed

Medtronic had a solid and steady quarter with revenue growth in all segments and geos. The company reported $8 billion in net revenue for a gain of 5.4%, led by the Diabetes segment. Sales of Diabetic supplies rose nearly 9.7% as reported, about 6% FX-neutral, followed by a 7% gain in Medical Surgical, 5.9% in Cardio and 4.7% in Neurology. 

All segments are supported by normalizing procedure volume and product innovation. Diabetic supplies were surprisingly strong given the rise of new weight control drugs but underpinned by the first full quarter of sales for the MiniMed units in the US. 

The margin news is mixed but favorable to shareholders. The GAAP net income and EPS improved more than 100% to over $900 million while adjusted income contracted. However, adjusted income outpaced the consensus estimate by 500 basis points, and FX headwinds offset the rest. The $0.08 FX headwind is worth 650 basis points in earnings, or enough to produce growth compared to last year. Regardless, the strength led to improved guidance, and both are helping to lift the stock price. 

Dividend health helps lift the Medtronic market

The guidance adjustment is slim but raises the midpoint for revenue and earnings above the consensus, with analysts adjusting their outlook for both. The takeaway is that earnings are expected to hold steady with a slight contraction this year and to resume growth next, more than offsetting this year's weakness and keeping the dividend health in good condition. 


Medtronic pays a healthy 3.6% yield with shares near $77.75. That's near the highest level the company has paid historically, and it comes at a discount to recent valuations, which is also substantial. 

The dividend payout ratio is near 50% of adjusted earnings, and the balance sheet is in good shape, with debt low and well-managed. Net debt is less than half of shareholder equity, about 25% of asset value, and distribution coverage is high, so the risk is minimal. With earnings expected to grow in 2024 and new product launches to sustain growth, dividend safety will improve for this high-yielding Dividend Aristocrat. 

Medtronic trades below fair value

Medtronic stock is trading in alignment with peers, about 15X for most and a discount to leaders like Abbott Laboratories NYSE: ABT and Stryker NYSE: SYK. Still, it pays the highest yield of the group while trading below fair value pricing. Fair value can be determined in many ways, including the analysts' consensus target, which is above the current price action. 

In this case, the analysts tracked by Marketbeat.com view this stock as a deep value because it trades below their price target range, about 2.5% at the low end and nearly 18% below the average. 

The price action in MDT moved to deep-value levels before the Q2 release and began to rebound the week before. Now, the rebound is gaining traction and confirming support at the critical $72.50 level. The rebound will likely continue, but the next hurdle is near $79.50 and may be tested soon. 

A move above $80 into the analysts' target range is likely if the market can get above that level. In this scenario, momentum will build, and the price action will continue up to the $90 level and analysts' consensus for fair value. If not, MDT shares could remain rangebound near current levels, but lower lows are not expected. 

mdt stock chart

→ This is the #1 Stock to Buy for the AI Tidal Wave (From Chaikin Analytics) (Ad)

Should you invest $1,000 in Medtronic right now?

Before you consider Medtronic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.

While Medtronic currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Abbott Laboratories (ABT)
4.8778 of 5 stars
$120.04+1.2%1.83%36.82Moderate Buy$120.00
Stryker (SYK)
4.9214 of 5 stars
$355.84+0.7%0.90%43.13Moderate Buy$331.52
Medtronic (MDT)
4.8077 of 5 stars
$85.06+1.7%3.24%27.09Hold$94.91
Compare These Stocks  Add These Stocks to My Watchlist 

Thomas Hughes

About Thomas Hughes

  • tmhughes.writeon@gmail.com

Contributing Author

Technical and Fundamental Analysis

Experience

Thomas Hughes has been a contributing writer for MarketBeat since 2019.

Areas of Expertise

Technical analysis, the S&P 500; retail, consumer, consumer staples, dividends, high-yield, small caps, technology, economic data, oil, cryptocurrencies

Education

Associate of Arts in Culinary Technology

Past Experience

Market watcher, trader and investor for numerous websites. Founded Passive Market Intelligence LLC to provide market research insights. 


Featured Articles and Offers

Search Headlines: